EP2675468A4 - Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna - Google Patents

Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna

Info

Publication number: EP2675468A4
Authority: EP; European Patent Office
Prior art keywords: mrna; decreasing; expression; breast cancer; treating breast
Prior art date: 2011-02-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP11858532.2A

Other languages

German (de)

French (fr)

Other versions

EP2675468A1 (en

Inventor

Chul Woo Kim

Ji Young Jang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bioinfra Inc

Original Assignee

Bioinfra Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-18

Filing date

2011-10-20

Publication date

2014-10-22

2011-10-20 Application filed by Bioinfra Inc filed Critical Bioinfra Inc

2013-12-25 Publication of EP2675468A1 publication Critical patent/EP2675468A1/en

2014-10-22 Publication of EP2675468A4 publication Critical patent/EP2675468A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP11858532.2A 2011-02-18 2011-10-20 Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna Withdrawn EP2675468A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR1020110014820A KR20120095263A (en)	2011-02-18	2011-02-18	Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna
PCT/KR2011/007849 WO2012111900A1 (en)	2011-02-18	2011-10-20	Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna

Publications (2)

Publication Number	Publication Date
EP2675468A1 EP2675468A1 (en)	2013-12-25
EP2675468A4 true EP2675468A4 (en)	2014-10-22

Family

ID=46672787

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11858532.2A Withdrawn EP2675468A4 (en)	2011-02-18	2011-10-20	Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna

Country Status (5)

Country	Link
EP (1)	EP2675468A4 (en)
JP (1)	JP2014506888A (en)
KR (1)	KR20120095263A (en)
CN (1)	CN103379914B (en)
WO (1)	WO2012111900A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103263676A (en) *	2013-02-07	2013-08-28	魏敏杰	Method for reversing drug resistance of breast cancer by using miR-487a
KR101681597B1 (en) *	2014-01-17	2016-12-01	주식회사 바이오인프라	Composition for overcoming resistance to her2 inhibitor comprising ant2 sirna
KR102211972B1 (en) *	2018-08-02	2021-02-04	엑소젠 피티이. 엘티디	Method for early diagnosis of breast cancer and monitoring after treatment using liquid biopsy multi-cancer gene biomarkers
CN112516317B (en) *	2020-12-10	2021-12-17	暨南大学附属第一医院（广州华侨医院）	A kind of pharmaceutical composition for preventing and treating cancer and its application
KR102604882B1 (en)	2021-07-01	2023-11-21	인천대학교 산학협력단	A novel specific anti-cancer and anti-inflammation siRNA and use thereof
CN120242073A (en) *	2025-03-26	2025-07-04	遵义医科大学珠海校区	A nano drug composition and its preparation method and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004067558A1 (en) *	2003-01-21	2004-08-12	Theraptosis	Means for regulating the expression of human isoforms of ant
WO2007117121A2 (en) *	2006-04-11	2007-10-18	Bioinfra Inc.	Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent
WO2008026946A2 (en) *	2006-08-30	2008-03-06	Genesis Research And Development Corporation Limited	Compositions and methods for the treatment and prevention of neoplastic disorders
WO2009126335A2 (en) *	2008-04-08	2009-10-15	University Of Florida Research Foundation, Inc.	Ant2 inhibitor compounds and methods of use thereof
US20110207798A1 (en) *	2006-04-11	2011-08-25	Bioinfra Inc.	Method for treating breast cancer using adenine nucleotide translocator 2 (ant2) sirna or ant2 shrna

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004064734A2 (en) *	2003-01-17	2004-08-05	Threshold Pharmaceuticals, Inc.	Combination therapies for the treatment of cancer

2011
- 2011-02-18 KR KR1020110014820A patent/KR20120095263A/en not_active Ceased
- 2011-10-20 CN CN201180067534.0A patent/CN103379914B/en not_active Expired - Fee Related
- 2011-10-20 EP EP11858532.2A patent/EP2675468A4/en not_active Withdrawn
- 2011-10-20 JP JP2013554383A patent/JP2014506888A/en active Pending
- 2011-10-20 WO PCT/KR2011/007849 patent/WO2012111900A1/en not_active Ceased

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004067558A1 (en) *	2003-01-21	2004-08-12	Theraptosis	Means for regulating the expression of human isoforms of ant
WO2007117121A2 (en) *	2006-04-11	2007-10-18	Bioinfra Inc.	Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent
US20110207798A1 (en) *	2006-04-11	2011-08-25	Bioinfra Inc.	Method for treating breast cancer using adenine nucleotide translocator 2 (ant2) sirna or ant2 shrna
WO2008026946A2 (en) *	2006-08-30	2008-03-06	Genesis Research And Development Corporation Limited	Compositions and methods for the treatment and prevention of neoplastic disorders
WO2009126335A2 (en) *	2008-04-08	2009-10-15	University Of Florida Research Foundation, Inc.	Ant2 inhibitor compounds and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FAURE-VIGNY H ET AL: "EXPRESSION OF OXIDATIVE PHOSPHORYLATION GENES IN RENAL TUMORS AND TUMORAL CELL LINES", MOLECULAR CARCINOGENESIS, ALAN LISS, NEW YORK, NY, US, vol. 16, no. 3, 1 January 1996 (1996-01-01), pages 165 - 172, XP009022330, ISSN: 0899-1987, DOI: 10.1002/(SICI)1098-2744(199607)16:3<165::AID-MC7>3.0.CO;2-G *
LE BRAS MORGANE ET AL: "Chemosensitization by knockdown of adenine nucleotide translocase-2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 66, no. 18, 15 September 2006 (2006-09-15), pages 9143 - 9152, XP002603476, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-4407 *
See also references of WO2012111900A1 *

Also Published As

Publication number	Publication date
CN103379914B (en)	2016-02-17
CN103379914A (en)	2013-10-30
WO2012111900A1 (en)	2012-08-23
KR20120095263A (en)	2012-08-28
EP2675468A1 (en)	2013-12-25
JP2014506888A (en)	2014-03-20

Publication	Publication Date	Title
EP2740742A4 (en)	2015-06-17	GENE GENE GENE KIF5B AND RET GENE, AND METHOD FOR DETERMINING THE EFFECTIVENESS OF ANTICANCER TREATMENT TARGETING THE CHIMERIC GENE
IL231171A0 (en)	2014-04-30	Rna engineered t cells for the treatment of cancer
EP2751267A4 (en)	2015-01-07	Methods for the treatment of breast cancer
IL237791A0 (en)	2015-05-31	Method of treating cancer
IL228738A0 (en)	2013-12-31	Antibodies for treatment of cancer
SG11201501653RA (en)	2015-04-29	Methods for the treatment of locally advanced breast cancer
ZA201400005B (en)	2014-10-29	Method for treating eczema
SG10201602369PA (en)	2016-05-30	Double-Stranded RNA (dsRNA) For Inhibiting Expression Of TMPRSS6
PH12014500248A1 (en)	2014-03-17	Treatment of breast cancer
SG11201503893RA (en)	2015-06-29	Method of treating cancer
ZA201205003B (en)	2013-09-25	Methods for treating breast cancer
EP2643001A4 (en)	2014-02-19	Method of treating cancer
EP2582374A4 (en)	2014-03-19	Methods for treating neurological conditions
IL228644A0 (en)	2013-12-31	Methods for treating cancer
EP2895206A4 (en)	2016-05-04	Method of treating cancer
IL232493A0 (en)	2014-06-30	Method of quantifying cancer treatment
IL228430A0 (en)	2013-12-31	Treatment of cancer
ZA201309254B (en)	2015-05-27	Method for treating non-small cell lung cancer
IL254964A0 (en)	2017-12-31	Method for treating breast cancer
EP2640390A4 (en)	2014-08-06	Methods of treating cancer
EP2675468A4 (en)	2014-10-22	Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna
PL2791344T3 (en)	2016-08-31	Method of treating byproducts from ethanol production
IL229705A0 (en)	2014-01-30	Methods of treating or preventing neurological diseases
HRP20130367T1 (en)	2013-06-30	Process for treating leather
HUE038149T2 (en)	2018-09-28	Method for the treatment of steels

Legal Events

Date	Code	Title	Description
2013-11-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-12-25	17P	Request for examination filed	Effective date: 20130912
2013-12-25	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2014-05-28	DAX	Request for extension of the european patent (deleted)
2014-10-22	A4	Supplementary search report drawn up and despatched	Effective date: 20140922
2014-10-22	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 38/16 20060101AFI20140916BHEP Ipc: A61P 35/00 20060101ALI20140916BHEP Ipc: C12N 15/113 20100101ALI20140916BHEP
2015-09-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2015-10-21	18D	Application deemed to be withdrawn	Effective date: 20150421